Endonovo Therapeutics Inc. (ENDV)
OTC PINK OTC PINK Primary Summary
ENDV Chart
Endonovo Therapeutics Inc. Dividends
Endonovo Therapeutics Inc. Earnings
| 31 Dec 2016 Date | | - Cons. EPS | - EPS |
| 30 Sep 2016 Date | | - Cons. EPS | - EPS |
| 30 Jun 2016 Date | | - Cons. EPS | - EPS |
| 31 Mar 2016 Date | | - Cons. EPS | - EPS |
| 31 Dec 2015 Date | | - Cons. EPS | - EPS |
| 31 Dec 2016 Date | | - Cons. EPS | - EPS |
| 30 Sep 2016 Date | | - Cons. EPS | - EPS |
| 30 Jun 2016 Date | | - Cons. EPS | - EPS |
| 31 Mar 2016 Date | | - Cons. EPS | - EPS |
| 31 Dec 2015 Date | | - Cons. EPS | - EPS |
Endonovo Therapeutics Inc. (ENDV) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Endonovo Therapeutics Inc. ever had a stock split?
Endonovo Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Alan Brian Collier CEO | OTC PINK Exchange | 29272H300 Cusip |
| US Country | 1 Employees | - Last Dividend | 20 Dec 2019 Last Split | - IPO Date |
Overview
Endonovo Therapeutics, Inc. is a pioneering biotechnology company dedicated to the development, manufacture, and distribution of non-invasive Electroceuticalâ„¢ medical devices aimed at the burgeoning field of regenerative medicine. Founded in 2008 and headquartered in Woodland Hills, California, the company stands at the forefront of therapeutic technology designed to heal soft tissue injuries, reduce chronic wounds, and alleviate post-operative pain and edema without invasive procedures. By leveraging advanced Electroceuticalâ„¢ technology, Endonovo Therapeutics, Inc. aims to transform the treatment landscape for cardiovascular, kidney, liver diseases, and various central nervous system disorders, significantly impacting patient recovery and quality of life.
Products and Services
The cornerstone of Endonovo Therapeutics' product lineup is the innovative SofPulse device. This section details its application and the wide array of conditions it addresses:
-
SofPulse:
A leading-edge, non-invasive Electroceuticalâ„¢ therapeutic device expressly designed for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. SofPulse represents a significant advancement in non-invasive medical treatments, offering patients a drug-free option to accelerate recovery and reduce reliance on pain medications.
-
Application in Cardiovascular and Peripheral Artery Diseases:
The Electroceuticals medical device is adept at addressing a range of cardiovascular conditions, actively contributing to the recovery and health of patients suffering from peripheral artery diseases and improving overall cardiovascular function.
-
Treatment of Chronic Kidney and Liver Diseases:
Endonovo's Electroceuticalâ„¢ technology is also being applied in the treatment of chronic kidney and liver diseases, including non-alcoholic steatohepatitis. This approach provides a new avenue of hope for patients with conditions previously considered difficult to treat, providing a non-invasive method to manage and potentially improve their disease states.
-
Use in Central Nervous System Disorders:
The technology has shown promise in treating central nervous system disorders, including traumatic brain injury, acute concussions, post-concussion syndrome, stroke, and multiple sclerosis. By employing Electroceuticals, Endonovo Therapeutics, Inc. offers a cutting-edge option for managing and potentially improving outcomes in these complex conditions.
Contact Information
